Document Classification

Section Type: RESULTS

Text: No significant differences in mean change [2 x SD] from baseline between aripiprazole (mean dose approximately 9 mg/day at endpoint ; range = 0. 7-15. 0 mg) and placebo were detected in the coprimary efficacy endpoints of Neuropsychiatric Inventory-Nursing Home Version (NPI-NH) Psychosis score (aripiprazole, -4. 53 [9. 23] ; placebo, -4. 62 [9. 56] ; F = 0. 02, df = 1, 222, p = 0. 883 [ANCOVA]) and Clinical Global Impression (CGI) - Severity score (aripiprazole, -0. 57 [1. 63] ; placebo, -0. 43 [1. 65] ; F = 1. 67, df = 1, 220, p = 0. 198 [ANCOVA]) at endpoint.